Fagron NV
OTC:ARSUF
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.03
26.807
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| BE |
|
Fagron NV
XBRU:FAGR
|
1.7B EUR |
Loading...
|
|
| US |
|
Mckesson Corp
NYSE:MCK
|
104.2B USD |
Loading...
|
|
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
68.9B USD |
Loading...
|
|
| US |
|
Cencora Inc
NYSE:COR
|
68.8B USD |
Loading...
|
|
| US |
|
Cardinal Health Inc
NYSE:CAH
|
50.6B USD |
Loading...
|
|
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
33.9B AUD |
Loading...
|
|
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
67.5B CNY |
Loading...
|
|
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.5B USD |
Loading...
|
|
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
64.2B CNY |
Loading...
|
|
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW |
Loading...
|
|
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
63.6B HKD |
Loading...
|
Market Distribution
| Min | -11 800% |
| 30th Percentile | 4.9% |
| Median | 11% |
| 70th Percentile | 26.6% |
| Max | 45 050% |
Other Profitability Ratios
Fagron NV
Glance View
Fagron NV is a Belgian multinational company that has woven specialized pharmaceutical compounding into the fabric of modern healthcare. Founded in 1990, the company's mission has always been to advance personalized medicine by focusing on the compounding sector, which involves tailoring and mixing pharmaceutical ingredients to produce unique medications tailored to the specific needs of patients. By transforming individual healthcare demands into bespoke pharmaceutical solutions, Fagron serves the global medical community by manufacturing and distributing both active and inactive pharmaceutical ingredients, as well as offering various base products. This strategic positioning not only supports healthcare professionals and pharmacies in delivering specialized patient care but also fortifies the company's commitment to improving global health outcomes. The key to Fagron's business model lies in its adept integration of innovation alongside therapeutic and technological solutions, ensuring they maintain a strong presence within the compounding market. The company particularly thrives on its ability to address niches in the pharmaceutical industry, ones often overlooked by large pharma entities due to scale inefficiencies. Through its three principal segments—Pharmaceutical Compounding, Raw Materials, and Innovative Concepts—Fagron generates revenue by supplying pharmacies and medical institutions worldwide, from small community pharmacies to large hospital networks. Its broad portfolio of over 30,000 products caters to a spectrum of needs, fostering both patient-specific and bulk pharmaceutical solutions. By combining quality, safety, and regulatory compliance with a keen market understanding, Fagron NV continues to sustain its role as a crucial player in the personalized medicine arena.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Fagron NV is 15.3%, which is above its 3-year median of 14.8%.
Over the last 3 years, Fagron NV’s Operating Margin has increased from 14.9% to 15.3%. During this period, it reached a low of 14.3% on Jun 30, 2023 and a high of 15.3% on Dec 31, 2024.